Oloctinebart Biosimilar Monoclonal Antibody (Galectin-3) for Research

Cat No.: GMP-Bios-INN-1311

Anti-LGALS3/GAL3 therapeutic antibody (Pre-made Oloctinebart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Oloctinebart (development code TB-006) is a humanized monoclonal antibody targeting galectin-3 (LGALS3). It is developed for fibrotic conditions. Further development details are under investigation.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1311-1mg 1mg 3090
GMP-Bios-INN-1311-10mg 10mg
GMP-Bios-INN-1311-100mg 100mg
GMP-Bios-INN-1311-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Oloctinebart biosimilar, Whole mAb, Anti-LGALS3/GAL3 Antibody: Anti-Galectin-3/Galectin 3/LGALS3/Gal-3 therapeutic antibody
INN Name Oloctinebart
Target LGALS3/GAL3
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G4
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2023
Year Recommended 2023
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech na